Cipher Pharmaceuticals, Inc. (CPH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

22.43 k

Shareholding (Sep 2024)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 25.10%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64

With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25

With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 371 Million (Small Cap)

P/E

22.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.13

Return on Equity

11.37%

Price to Book

2.48

Revenue and Profits:

Net Sales:

19 Million

(Quarterly Results - Jun 2025)

Net Profit:

8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.01%

6 Months

18.33%

1 Year

-6.6%

2 Years

135.9%

3 Years

317.0%

4 Years

760.82%

5 Years

1535.56%

Cipher Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Cipher Pharmaceuticals Adjusts Valuation Amid Strong Financial Performance and Market Position

Cipher Pharmaceuticals, Inc. has recently experienced a change in its evaluation, reflecting adjustments in its financial metrics and market position. The company showcases strong management efficiency and notable growth in net profit, alongside solid operating cash flow and sales figures, indicating a balanced valuation relative to industry standards.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.30%

EBIT Growth (5y)

-11.25%

EBIT to Interest (avg)

12.64

Debt to EBITDA (avg)

0.38

Net Debt to Equity (avg)

0.17

Sales to Capital Employed (avg)

0.27

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

37.30%

ROE (avg)

25.10%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.49

EV to EBIT

39.27

EV to EBITDA

19.73

EV to Capital Employed

2.32

EV to Sales

5.88

PEG Ratio

Dividend Yield

ROCE (Latest)

5.91%

ROE (Latest)

11.37%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.56% vs 4.24% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 115.79% vs -19.15% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.50",
          "val2": "17.20",
          "chgp": "7.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.40",
          "val2": "6.00",
          "chgp": "56.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "8.20",
          "val2": "3.80",
          "chgp": "115.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "373.00%",
          "val2": "195.20%",
          "chgp": "17.78%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 59.79% vs 6.32% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -42.55% vs -20.75% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "45.70",
          "val2": "28.60",
          "chgp": "59.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.50",
          "val2": "15.20",
          "chgp": "-17.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.80",
          "val2": "27.50",
          "chgp": "-42.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.90%",
          "val2": "474.10%",
          "chgp": "-32.02%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

18.50

17.20

7.56%

Operating Profit (PBDIT) excl Other Income

9.40

6.00

56.67%

Interest

0.50

0.70

-28.57%

Exceptional Items

0.00

Consolidate Net Profit

8.20

3.80

115.79%

Operating Profit Margin (Excl OI)

373.00%

195.20%

17.78%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.56% vs 4.24% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 115.79% vs -19.15% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

45.70

28.60

59.79%

Operating Profit (PBDIT) excl Other Income

12.50

15.20

-17.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

15.80

27.50

-42.55%

Operating Profit Margin (Excl OI)

153.90%

474.10%

-32.02%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 59.79% vs 6.32% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -42.55% vs -20.75% in Dec 2023

All Annual Results

Company CV

About Cipher Pharmaceuticals, Inc.

Cipher Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Company Coordinates

Company Details

209 Oak Park Blvd, Suite 501 , OAKVILLE ON : L6H 0M2

Tel: 1 905 60258401 416 5199442

http://www.cipherpharma.com/

Registrar Details

Cipher Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROE of 25.10%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64

With a growth in Net Profit of 116.61%, the company declared Very Positive results in Jun 25

With ROE of 11.37%, it has a fair valuation with a 2.70 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Cipher Pharmaceuticals Adjusts Valuation Amid Strong Financial Performance and Market Position

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Cipher Pharmaceuticals, Inc.

Company Coordinates